United Therapeutics Stock (NASDAQ:UTHR), Trade Ideas

United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

UTHR

Biotech

Earnings

Large Cap

News

Health Care

Legal

General

LQDA

Legal battle unfolds as United Therapeutics challenges FDA&#39;s handling of Liquidia&#39;s drug approval process. Explore the implications on PH-ILD, potential 30-month stay, and recent financial performance.

United Therapeutics&#39; Challenges FDA Over Liquidia&#39;s Drug Approval Process, Clocks Strong Q4 Earnings

Analyst Color

Upgrades

Price Target

Small Cap

Analyst Ratings

Movers

Trading Ideas

United Therapeutics Corporation (NASDAQ: UTHR) is in a patent dispute with Liquidia Corp (NASDAQ: 

This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate

Pre-Market Outlook

Markets

NRDS

RIVN

ROAD

TEVA

URBN

VIAV

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Teva Pharmaceutical To Rally Around 58%? Here Are 10 Top Analyst Forecasts For Monday

United Therapeutics Corporation - Common Stock

United Therapeutics Corp

Liquidia Says Judge Andrews Has Set Aside Injunction Issued In August 2022 In Lawsuit Filed By United Therapeutics, Hence FDA Is No Longer Enjoined From Issuing Final Approval Of Liquidia New Drug Application For Yutrepia (Treprostinil) Inhalation Powder

<h3>Gainers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares moved upwards by 7.36% to $0.78. The company's market cap stands at $42.8 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares moved upwards by 6.66% to $0.32. The company's market cap stands at $10.9 million. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares rose 6.44% to $7.75. The market value of their outstanding shares is at $5.8 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares increased by 6.38% to $0.5. The market value of their outstanding shares is at $4.6 million. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock increased by 5.52% to $2.65. The company's market cap stands at $43.0 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) stock decreased by 22.9% to $0.29 during Tuesday's after-market session. The company's market cap stands at $23.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock fell 11.34% to $1.02. The company's market cap stands at $15.0 million. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) shares decreased by 9.84% to $1.1. The market value of their outstanding shares is at $40.2 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) shares decreased by 7.21% to $3.6. The market value of their outstanding shares is at $4.2 million. </li>
<li>United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) shares declined by 7.21% to $230.0. The company's market cap stands at $10.8 billion. </li>
<li>ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) stock decreased by 6.46% to $0.58. The market value of their outstanding shares is at $10.0 million. As per the press release, Q4 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AKLI

APLM

BSGM

CARA

COEP

ESLA

IRIX

MIRA

TTNP

VRPX

12 Health Care Stocks Moving In Tuesday's After-Market Session

WIIM

United Therapeutics shares are trading higher after the company announced a $1 billion accelerated share repurchase program.

United Therapeutics Corporation (Nasdaq:&nbsp;UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to&nbsp;$1 billion&nbsp;of United Therapeutics&#39; common stock. This program builds on United Therapeutics&#39; planned&nbsp;$400 million&nbsp;paydown of its revolving credit facility in 2024, of which&nbsp;$100 million&nbsp;was paid down during the&nbsp;first quarter&nbsp;of 2024.

Buybacks

United Therapeutics Announces $1B Accelerated Share Repurchase Program

Liquidia&rsquo;s investigational product is currently tentatively approved by the FDA for the treatment of pulmonary arterial hypertension (PAH) but not PH-ILD. In this litigation, the Company alleges that Liquidia&rsquo;s product for use in pulmonary hypertension associated with interstitial lung disease (PH-ILD) infringes the Company&rsquo;s U.S. Patent No. 11,826,327 (the &rsquo;327 patent), which expires in 2042. The &rsquo;327 patent generally covers improving exercise capacity in patients suffering from PH-ILD by administering treprostinil by inhalation. In its preliminary injunction motion, the Company asked the district court to enjoin Liquidia from marketing its product for PH-ILD until the court can adjudicate the Company&rsquo;s infringement claims.
&nbsp;

United Therapeutics Filed Motion In U.S. District Court For The District Of Delaware For Preliminary Injunction In Its Patent Litigation With Liquidia Technologies' Efforts To Seek FDA Approval For PH-ILD For Its Inhaled Treprostinil Product-8K

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated United Therapeutics and provided 12-month price targets. The average target is $288.25, accompanied by a high estimate of $330.00 and a low estimate of $215.00. Marking an increase of 35.33%, the current average surpasses the previous average price target of $213.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1708610436_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of United Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liana Moussatos</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$308.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Roanna Ruiz</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$330.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to United Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of United Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>About United Therapeutics</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Financial Insights: United Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: United Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2023, the company achieved a revenue growth rate of approximately 18.1%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 43.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): United Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.81%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): United Therapeutics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 3.91%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss United Therapeutics Stock

Wedbush analyst Liana Moussatos reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform and maintains $308 price target.

Reiteration

Wedbush Reiterates Outperform on United Therapeutics, Maintains $308 Price Target

HC Wainwright &amp; Co. analyst Andrew Fein reiterates United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Buy and maintains $300 price target.

HC Wainwright & Co. Reiterates Buy on United Therapeutics, Maintains $300 Price Target

Wednesday,&nbsp;United Therapeutics Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) initiated legal action against the FDA, claiming that the FDA wrongly allowed&nbsp;Liquidia Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) to deviate from established&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37231366/united-therapeutics-commences-litigation-to-ensure-fairness-in-the-drug-review-process" rel="noreferrer noopener">rules in the drug approval process</a>.&nbsp;
The litigation focuses on the FDA&#8217;s handling of Liquidia&#8217;s amendment to a pending new drug application (NDA) related to its proposed inhaled dry powder treprostinil product, seeking to add a second indication for pulmonary hypertension associated with interstitial lung disease (PH-ILD).&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37069483/this-united-therapeutics-analyst-is-no-longer-bearish-expects-mid-decade-4b-revenue" rel="noreferrer noopener">This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate</a>.
United Therapeutics contends that FDA rules require a new NDA for such a second indication rather than an amendment to an existing one.
The company also asserts that, under the Hatch-Waxman Act, Liquidia&#8217;s decision to file an amendment instead of a new NDA allowed it to avoid a potential 30-month stay on approval for PH-ILD.&nbsp;
This stay would be triggered if a timely patent infringement action is filed, preventing FDA approval until the litigation is resolved.&nbsp;
United Therapeutics had previously sued Liquidia for alleged infringement of a patent related to the PH-ILD indication.&nbsp;
The ongoing patent infringement case contends that Liquidia&#8217;s actions in seeking approval for PH-ILD infringe on United Therapeutics&#8217; patent rights.&nbsp;
The lawsuit is pending in the U.S. District Court for the District of Delaware.&nbsp;
If successful in its legal action against the FDA, United Therapeutics aims to secure a stay of up to 30 months on Liquidia&#8217;s final approval for PH-ILD, allowing for the resolution of the patent infringement litigation.
United Therapeutics reported a fourth-quarter 2023 EPS of $4.36, up from $2.67 a year ago,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $4.19</a>.
The company&#8217;s sales increased 25% to $614.70 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/b37231427/united-therapeutics-corporation-reports-fourth-quarter-and-full-year-2023-financial-results" rel="noreferrer noopener">consensus of $575.87 million</a>.
Total Tyvaso revenues grew by 45% to $350.6 million in the fourth quarter of 2023, compared to $242.3 million a year ago, primarily due to an increase in quantities sold, driven by the commercial launch of Tyvaso DPI in June 2022 and continued growth in utilization by PH-ILD patients.
Price Action:&nbsp;UTHR shares are up 0.87% at $216.03 on the last check Wednesday.

United Therapeutics' Challenges FDA Over Liquidia's Drug Approval Process, Clocks Strong Q4 Earnings

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) reported quarterly earnings of $4.36 per share which beat the analyst consensus estimate of $4.19 by 4.06 percent. This is a 63.3 percent increase over earnings of $2.67 per share from the same period last year. The company reported quarterly sales of $614.70 million which beat the analyst consensus estimate of $575.87 million by 6.74 percent. This is a 25.07 percent increase over sales of $491.50 million the same period last year.

United Therapeutics Q4 GAAP EPS $4.36 Beats $4.19 Estimate, Sales $614.70M Beat $575.87M Estimate

United Therapeutics Has Commenced Litigation Related To The FDA Inappropriately Denying United Therapeutics' Right To Obtain Stay Of Liquidia's Final Approval Until United Therapeutics' Pending Patent Infringement Claim Against Liquidia Can Be Resolved

ACVA

ALIT

AMSF

ANSS

ATNI

BALY

BELFA

BELFB

BLCO

BRDG

BROS

BRSP

CAKE

CCAP

CCRN

CCSI

CENX

CHDN

CHRD

CNNE

COKE

CSTE

CSTM

DINO

DOCN

ECPG

ERII

ESEA

ETSY

EXAS

FIVN

GATO

GKOS

GLBE

GOOD

GRMN

GSHD

ICLR

INSG

IONS

JACK

JOBY

KALU

LANV

LCID

LIVN

LUNG

MATV

MGRC

MTLS

NDSN

NEXA

NGVT

NOVA

NVDA

NVRO

NYMT

OBDC

Earnings Scheduled For February 21, 2024

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-21. Here's what investors need to know before the announcement.
Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $4.19. 
United Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.30, which was followed by a 1.83% increase in the share price the next day.
Here's a look at United Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.08</td>
<td>4.41</td>
<td>4.52</td>
<td>4.51</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>5.38</td>
<td>5.24</td>
<td>4.86</td>
<td>2.67</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.83%</td>
<td>-3.73%</td>
<td>-1.23%</td>
<td>1.89%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1708455676_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of United Therapeutics were trading at $214.73 as of February 19. Over the last 52-week period, shares are down 11.68%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/UTHR/earnings">To track all earnings releases for United Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For United Therapeutics

United Therapeutics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uthr#NASDAQ">UTHR</a>) is in a <a href="https://www.benzinga.com/general/biotech/23/12/36328394/why-is-pulmonary-hypertension-focused-liquidia-stock-soaring-today">patent dispute with Liquidia Corp (NASDAQ: </a><a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>).
While the company&rsquo;s franchise position within the &ldquo;highly attractive&rdquo; pulmonary arterial hypertension (PAH) market is unique, its key growth asset faces significant competition, according to Goldman Sachs.
The United Therapeutics Analyst: Chris Shibutani upgraded the rating for United Therapeutics from Sell to Neutral, while raising the price target from $213 to $215.
The United Therapeutics Thesis: The company&rsquo;s Tyvaso will face headwinds from the anticipated entry of Merck &amp; Co Inc&rsquo;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrk#NYSE">MRK</a>) sotatercept and from Liquidia&rsquo;s Yutrepia, &ldquo;which is tentatively approved for PAH,&rdquo; Shibutani said in the upgrade note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Liquidia is awaiting the FDA&rsquo;s decision to potentially expand Yutrepia&rsquo;s tentatively approved label for PH-ILD (pulmonary hypertension associated with interstitial lung disease), the indication that is the &ldquo;key growth driver&rdquo; for United Therapeutics and essential for the company to be in a position to achieve the mid-decade $4 billion revenue run rate objective that its management team had provided in 2023, the analyst stated.
&ldquo;Efforts are now underway to further expand manufacturing to satisfy potential future needs if Tyvaso&rsquo;s development in pulmonary fibrosis (TETON studies) is successful,&rdquo; he added.
UTHR Price Action: Shares of United Therapeutics had risen by 1.64% to $215.83 at the time of publication on Monday.
&nbsp;

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>UBS raised the price target for Urban Outfitters, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/urbn#NASDAQ">URBN</a>) from $21 to $41. UBS analyst Jay Sole upgraded the stock from Sell to Neutral. Urban Outfitters shares gained 2.2% to close at $42.53 on Friday. <a href="https://www.benzinga.com/quote/URBN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs boosted United Therapeutics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uthr#NASDAQ">UTHR</a>) price target from $213 to $215. Goldman Sachs analyst Chris Shibutani upgraded the stock from Sell to Neutral. United Therapeutics shares rose 0.3% to close at $212.34 on Friday. <a href="https://www.benzinga.com/quote/UTHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank boosted the price target for Mohawk Industries, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mhk#NYSE">MHK</a>) from $98 to $152. Deutsche Bank analyst Joe Ahlersmeyer upgraded the stock from Hold to Buy. Mohawk Industries shares gained 0.4% to close at $110.01 on Friday. <a href="https://www.benzinga.com/quote/MHK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc raised NerdWallet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nrds#NASDAQ">NRDS</a>) price target from $18 to $20. Keybanc analyst Justin Patterson maintained an Overweight rating. NerdWallet shares rose 2% to close at $15.52 on Friday. <a href="https://www.benzinga.com/quote/NRDS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler boosted the price target for Teva Pharmaceutical Industries Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/teva#NYSE">TEVA</a>) from $12 to $19. Piper Sandler analyst David Amsellem upgraded the stock from Neutral to Overweight. Teva Pharmaceutical shares fell 0.7% to close at $12.01 on Friday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised the price target for Assurant, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aiz#NYSE">AIZ</a>) from $170 to $182. Keefe, Bruyette &amp; Woods analyst Thomas McJoynt-Griffith downgraded the stock from Outperform to Market Perform. Assurant shares fell 0.1% to close at $174.49 on Friday. <a href="https://www.benzinga.com/quote/AIZ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel increased Viavi Solutions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viav#NASDAQ">VIAV</a>) price target from $10 to $13. Stifel analyst Ruben Roy upgraded the stock from Hold to Buy. Viavi Solutions shares gained 2.4% to close at $8.91 on Friday. <a href="https://www.benzinga.com/quote/VIAV/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays cut Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) price target from $25 to $16. Barclays analyst Dan Levy downgraded the stock from Overweight to Equal-Weight. Rivian Automotive shares gained 3.5% to close at $16.68 on Friday. <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised Construction Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/road#NASDAQ">ROAD</a>) price target from $46 to $50. Baird analyst Andrew Wittmann downgraded the stock from Outperform to Neutral. Construction Partners shares fell 7% to close at $46.81 on Friday. <a href="https://www.benzinga.com/quote/ROAD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley boosted XPO, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpo#NYSE">XPO</a>) price target from $75 to $80. Morgan Stanley analyst Ravi Shanker downgraded the stock from Equal-Weight to Underweight. XPO shares gained 2.4% to close at $120.84 on Friday. <a href="https://www.benzinga.com/quote/XPO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/02/37062484/waste-management-goodyear-tire-and-3-stocks-to-watch-heading-into-monday"> Waste Management, Goodyear Tire And 3 Stocks To Watch Heading Into Monday </a>

Goldman Sachs analyst Chris Shibutani upgrades United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) from Sell to Neutral and raises the price target from $213 to $215.

Goldman Sachs Upgrades United Therapeutics to Neutral, Raises Price Target to $215

Leerink Partners analyst Roanna Ruiz initiates coverage on United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) with a Outperform rating and announces Price Target of $330.

Initiation

Leerink Partners Initiates Coverage On United Therapeutics with Outperform Rating, Announces Price Target of $330

Liquidia Said On Jan 22, United Therapeutics Filed A Stipulation To Dismiss All Claims In The New Hatch-Waxman Litigation Related To '793 Paten

As a result of today&#39;s decision, Liquidia will immediately seek to set aside the injunction issued by the U.S. District Court for the District of Delaware (District Court) in the lawsuit filed by United Therapeutics (UTHR) under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act) and pursue final regulatory approval of YUTREPIA by the U.S. Food and Drug Administration (FDA).

Liquidia Says Federal Circuit Affirmed Earlier PTAB Decision To Invalidate All Claims Of United Therapeutics Patent No. 10,716,793 ('793 Patent)

Liquidia Corp&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lqda#NASDAQ">LQDA</a>) stock jumped after a&nbsp;<a class="editor-rtfLink" href="https://storage.courtlistener.com/recap/gov.uscourts.cafc.20130/gov.uscourts.cafc.20130.52.0.pdf" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">win</a>&nbsp;in a patent dispute with&nbsp;United Therapeutics Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uthr#NASDAQ">UTHR</a>) revolving around U.S. Patent 10,716,793 (the &rsquo;793 patent).
&quot;We have considered United Therapeutics (UTC&#39;s) remaining arguments and find them unpersuasive,&quot; the three judge panel wrote in its decision. &quot;For the reasons provided above, we affirm the Board&#39;s unpatentability determination.&quot;
United Therapeutics owns the &rsquo;793 patent, which is directed to treating pulmonary hypertension (PAH) and PAH-associated with interstitial lung disease by inhaling treprostinil, which United Therapeutics markets as Tyvaso.
In November 2021, the FDA&nbsp;<a class="editor-rtfLink" href="https://www.liquidia.com/news-releases/news-release-details/liquidia-corporation-reports-full-year-2021-financial-results" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">issued</a>&nbsp;a tentative approval of Yutrepia (treprostinil) inhalation powder, but it cannot yet be marketed, pending resolution of Hatch-Waxman litigation commenced by United Therapeutics in June 2020.&nbsp;
In its&nbsp;<a class="editor-rtfLink" href="https://www.liquidia.com/news-releases/news-release-details/liquidia-corporation-reports-third-quarter-2023-financial#:~:text=About%20YUTREPIA%E2%84%A2(treprostinil)%20inhalation%20powder&amp;text=In%20July%202023%20%2C%20Liquidia%20filed,24%2C%202024%20for%20the%20amendment." style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">Q3</a>&nbsp;earnings release, Liquidia said that the FDA accepted the amendment to the New Drug Application (NDA) for Yutrepia to add the indication of pulmonary hypertension associated with interstitial lung disease (PH-ILD) to the label and has set a Prescription Drug User Fee Act (PDUFA) goal date of January 24, 2024.&nbsp;
Final approval of the PH-ILD indication cannot occur until the new clinical investigation exclusivity granted to Tyvaso expires on March 31, 2024.&nbsp;
Price Action:&nbsp;LQDA shares are up 42.80% at $11.26, and UTHR stock is down 4.39% at $221.75 on the last check Wednesday.

Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on United Therapeutics (UTHR – Research Report), Regene...

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Regeneron (REGN) and Intuitive Surgical (ISRG)

Merck wins FDA approval of sotatercept for rare lung disease

Merck hits all-time high after FDA nod for lung disease therapy

Liquidia gains after court win in patent dispute with United Therapeutics

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV – Research Report), United Thera...

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)

United Therapeutics motion for restraining order over Liquidia's Yutrepia denied

The biotech industry's prospects appear promising due to government support, regulatory changes, innovative therapies, and a focus on personalized medicine. Therefore, investors could consider buying fundamentally strong biotech stocks such as United Therapeutics (UTHR), TRACON Pharmaceuticals (TCON), and Corcept Therapeutics (CORT). Read more... The focus on treating rare diseases, the development of innovative vaccines and therapies, changes in regulations, increased investments into R&amp;D, and the use of advanced technology are driving the growth of the biotech sector. Ongoing innovations in the biotech space meet demands for advanced healthcare, especially for chronic and aging-related conditions.
Amid this backdrop, investors could consider buying fundamentally strong biotech stocks: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>), TRACON Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/TCON/">TCON</a>), and Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>).
The world's ever-rising need for quality healthcare, growing demand for targeted therapies, robust drug pipelines, and innovations in genetic engineering boost the biotech industry's prospects. In a recent survey by ICON of over 130 biotech executives, <a href="https://investor.iconplc.com/news-releases/news-release-details/biotech-companies-increase-rd-spend-highlight-complexity">60% of respondents</a> expected to increase R&amp;D spending, while only 2% planned to reduce funding.
The biotech sector's growth is also being fueled by leveraging the power of AI and machine learning. AI is revolutionizing drug discovery, improving R&amp;D processes, and aiding in efficient manufacturing.
Furthermore, the global biotechnology market is projected to reach <a href="https://www.grandviewresearch.com/industry-analysis/biotechnology-market">$3.88 trillion by 2030</a>, expanding at a CAGR of 14% from 2024 to 2030. Investors' interest in biotech stocks is evident from the SPDR S&amp;P Biotech ETF's (<a href="https://stocknews.com/stock/XBI/">XBI</a>) 28% returns over the past six months.
Considering these conducive trends, let's analyze the fundamental aspects of the three <a href="https://stocknews.com/category/biotech/">Biotech</a> picks, beginning with the third choice.
Stock #3: United Therapeutics Corporation (<a href="https://stocknews.com/stock/UTHR/">UTHR</a>)
UTHR is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases internationally.
In terms of forward non-GAAP P/E, UTHR's 9.39x is 51.4% lower than the 19.33x industry average. Its 2.59x forward <a href="https://www.investopedia.com/terms/e/enterprisevaluesales.asp">EV/Sales</a> is 27.1% lower than the 3.55x industry average. Likewise, its 5x forward EV/EBITDA is 61.2% lower than the 12.89x industry average.
UTHR's total revenues for the fourth quarter, which ended December 31, 2023, increased 25.1% year-over-year to $614.70 million. Its operating income rose 48.1% year-over-year to $260.10 million. The company's net income came in at $217.10 million, or $4.36 per share, up 64.3% and 63.3% over the prior-year quarter, respectively.
For the quarter ended March 31, 2024, UTHR's EPS is expected to increase 16% year-over-year to $5.64. Its revenue for the same quarter is expected to increase 22.9% year-over-year to $622.92 million. It surpassed the consensus EPS estimates in each of the trailing four quarters. UTHR's stock has gained 7.9% year-to-date to close the last trading session at $237.24.
UTHR's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect solid prospects. It has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.
It is ranked #9 out of 361 stocks in the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry. It has an A grade for Value and a B for Quality. <a href="https://stocknews.com/stock/UTHR/">Click here</a> to see UTHR's Growth, Momentum, Stability, and Sentiment ratings.
Stock #2: TRACON Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/TCON/">TCON</a>)
TCON is a biopharmaceutical company that focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States.
In terms of the trailing-12-month Price/Sales, TCON's 0.35x is 91% lower than the 3.90x industry average.
For the fiscal fourth quarter that ended on December 31, 2023, TCON's revenue amounted to $3.05 million. Its income from operations came in at $407 thousand, compared to a loss from operations of $5.83 million in the year-ago quarter.
Additionally, the company's net income and earnings per share stood at $439 thousand and $0.01, respectively, compared to the previous year's net loss and loss per share of $7 million and $0.31.
Street expects TCON's EPS for the quarter ended March 31, 2024, to remain negative. Over the past six months, the stock has declined 30.3% to close the last trading session at $16.42.
TCON's positive outlook is reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.
It has an A grade for Growth and a B for Value, Sentiment, and Quality. It is ranked #8 in the same industry. To see TCON's ratings for Momentum and Stability, <a href="https://stocknews.com/stock/TCON/">click here</a>.
Stock #1: Corcept Therapeutics Incorporated (<a href="https://stocknews.com/stock/CORT/">CORT</a>)
CORT engages in discovering and developing drugs for treating severe metabolic, oncologic, endocrine, and neurological disorders. It offers Korlym tablets for hyperglycemia in adults with endogenous Cushing's syndrome and is developing several other medications in clinical trials for various conditions.
In terms of forward EV/EBIT, CORT's 14.52x is 10.2% lower than the 16.17x industry average. Also, its 3.35x forward EV/Sales is 5.6% lower than the 3.55x industry average.
For the fourth quarter, which ended December 31, 2023, CORT's net product revenue grew 31.4% year-over-year to $135.41 million. The company's net income attributable to common stockholders rose 88.1% from the year-ago value to $31.14 million. Its net income per common share was $0.28, up 100% year-over-year.
In addition, as of December 31, 2023, its total assets stood at $621.52 million, compared to $583.43 million as of December 31, 2022.
Analysts expect CORT's EPS for the quarter ended March 31, 2024, to increase 61.4% year-over-year to $0.23. Its revenue for the same quarter is expected to increase 33.3% year-over-year to $140.80 million. It surpassed the consensus EPS estimates in three of the trailing four quarters. Over the past year, the stock has gained 8% to close the last trading session at $23.82.
It's no surprise that CORT has an overall rating of A, which translates to a Strong Buy in our proprietary rating system.
It has an A grade for Value and Quality and a B for Growth. Within the Biotech industry, it is ranked #6. Beyond what we stated above, we also have given CORT grades for Momentum, Stability, and Sentiment. Get all CORT ratings <a href="https://stocknews.com/stock/CORT/">here</a>.
What To Do Next?
43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.
<a href="https://report.stocknews.com/sign-up/stock-market-outlook-2024/?formplacement=artbotad_smo24_rep">2024 Stock Market Outlook &gt;</a>
&nbsp;

<hr />
UTHR shares were trading at $235.08 per share on Friday morning, down $2.16 (-0.91%). Year-to-date, UTHR has gained 6.91%, versus a 8.32% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/uthr-cort-tcon-3-promising-biotech-stocks-driving-weekly-gains/>3 Promising Biotech Stocks Driving Weekly Gains</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Promising Biotech Stocks Driving Weekly Gains

United Therapeutics (UTHR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Roanna Ruiz ...

United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating

Wells Fargo analyst Tiago Fauth maintained a Buy rating on United Therapeutics (UTHR – Research Report) yesterday and set a price target of $325.00...

Wells Fargo Sticks to Their Buy Rating for United Therapeutics (UTHR)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on United Therapeutics (UTHR – Research Report) and Add...

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)

ADUS

CORT

IMNM

ISRG

REGN

TCON

Press Releases

United Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and Merger

United Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare Conference

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024

United Therapeutics Commences Litigation to Ensure Fairness in the Drug Review Process

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial Results

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference